Furthermore, possible effects on AD of anti-diabetic drugs such as pioglitazone, which reduce insulin resistance or the Glucagon-Like Polypeptide-1 receptor agonist (GLP-1 RA), with an effect on low-grade inflammation, are being investigated (13). Here, GLP1R is linked to Alzheimer disease.